AI app aims to catch deadly skin cancer early in rare disease patients
NCT ID NCT05843994
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is developing an artificial intelligence app to detect squamous cell carcinoma (a type of skin cancer) in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic blistering condition. Twenty adults with RDEB and a history of skin cancer will submit photos of their skin through an online survey. The goal is to train the AI to recognize cancer from patient-taken photos, which could eventually lead to a home-use app for early detection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
online survey and photograph submission
What this could lead to
If successful, this could lead to a home-use app that helps patients and doctors spot skin cancer early, improving outcomes.
What could go wrong
This is an early-stage study with only 20 participants, and the AI may not work as well on real-world photos as it does on professional images.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Dermatology, Northwestern University Feinberg School of Medicine and Lurie Children's Hospital
Chicago, Illinois, 60611, United States